Report Overview
The Global Postbiotic Supplements Market size is expected to be worth around USD 16.5 Billion by 2035, from USD 5.5 Billion in 2025, growing at a CAGR of 11.7% during the forecast period from 2026 to 2035. In 2025, North America held a dominant market position, capturing more than a 36.34% share, holding USD 1.9 Billion revenue.
The Postbiotic Supplements industry is emerging as an important segment of the global nutritional and functional health industry. Postbiotics are preparations of inanimate microorganisms and their components that provide health benefits to the host.
According to the International Scientific Association for Probiotics and Prebiotics (ISAPP), the definition was established through an expert consensus published on May 4, 2021, in Nature Reviews Gastroenterology & Hepatology. These preparations generally contain heat-inactivated bacterial cells, cell-wall components and other microbial materials that may support intestinal health, immune function and overall wellness.
From an industrial perspective, postbiotic supplements are manufactured through controlled microbial fermentation, biomass collection, microbial inactivation, drying and formulation. Manufacturers commonly work with bacterial strains such as Lactobacillus and Bifidobacterium to develop functional ingredients.
Thermal treatment and other controlled inactivation techniques help convert microbial cultures into non-living preparations while retaining relevant biological components. Spray drying, encapsulation and powder-processing technologies are also important for improving ingredient stability and supporting integration into capsules, tablets, sachets and functional beverages.
According to the US Centers for Disease Control and Prevention (CDC), 57.6% of American adults aged 20 years and above reported using dietary supplements during 2017–2018. Supplement consumption was higher among women at 63.8%, compared with 50.8% among men. Although these figures represent the overall dietary supplement industry rather than postbiotic products specifically, they demonstrate an established consumer base for nutritional supplementation. Growing awareness of gut microbiome health, immune support and functional nutrition is creating opportunities for postbiotic-based product development.
Government regulations and food safety requirements will also influence the industry’s future development. In the United States, the Food and Drug Administration (FDA) requires manufacturers introducing dietary supplements containing applicable new dietary ingredients to submit a safety notification at least 75 days before marketing. This requirement is established under Section 413 of the Federal Food, Drug, and Cosmetic Act.
In Europe, Regulation (EU) 2015/2283, applicable from January 1, 2018, provides the regulatory framework for novel foods, including certain ingredients derived from microorganisms. These requirements encourage manufacturers to strengthen ingredient identification, safety assessment, manufacturing documentation and product quality.
Key Takeaways
- Postbiotic Supplements Market size is expected to be worth around USD 16.5 Billion by 2035, from USD 5.5 Billion in 2025, growing at a CAGR of 11.7%.
- Capsules and Tablets held a dominant market position, capturing more than a 42.00% share.
- Digestive Health held a dominant market position, capturing more than a 46.45% share.
- Pharmacies & Health Stores held a dominant market position, capturing more than a 38.90% share.
- North America dominated the Iron and Steel Making Market, accounting for 36.34% share, valued at USD 1.9 billion.
By Product Analysis
Capsules and Tablets – Dominant Segment
In 2025, “Capsules and Tablets” held a dominant market position, capturing more than a 42.00% share. This segment benefits from convenient consumption, accurate dosage measurement and easy storage, making it a preferred format for postbiotic supplement manufacturers and consumers. Capsules and tablets also allow manufacturers to incorporate standardized postbiotic ingredients into compact formulations without requiring consumers to prepare or mix the product. Their suitability for retail distribution, longer storage requirements and established supplement manufacturing processes further support their commercial acceptance.
The growing focus on digestive health, immune support and preventive nutrition is encouraging manufacturers to introduce capsule- and tablet-based postbiotic formulations. These products also provide opportunities for combining postbiotic ingredients with vitamins, minerals and other functional ingredients. According to the US Centers for Disease Control and Prevention (CDC), its National Health and Nutrition Examination Survey (NHANES) recognizes tablets and capsules as established dietary supplement dosage forms.
By Application Analysis
Digestive Health – Dominant Application Segment
In 2025, “Digestive Health” held a dominant market position, capturing more than a 46.45% share. The segment’s leading position is supported by growing consumer interest in gut health, intestinal balance and overall digestive wellness. Postbiotic supplements are gaining attention because they contain inactivated microorganisms and their components, which can provide health benefits without requiring live bacterial cultures. This makes them suitable for manufacturers developing digestive health formulations in capsules, tablets and powders.
“Immune Support” is an important application segment in the Postbiotic Supplements Market, supported by increasing consumer interest in maintaining immune health and strengthening overall wellness. Postbiotic ingredients are attracting attention because they contain inactivated microorganisms and microbial components that may interact with the body’s immune system. Their potential role in supporting immune responses is encouraging supplement manufacturers to develop specialized formulations for daily nutritional use. These products are increasingly being explored in capsules, tablets, powders and functional nutrition products.
By Distribution Channel Analysis
Pharmacies & Health Stores – Dominant Channel Supported by Consumer Trust and Product Availability
In 2025, “Pharmacies & Health Stores” held a dominant market position, capturing more than a 38.90% share. This segment benefits from consumer trust, product accessibility and the availability of professional guidance when purchasing nutritional supplements. Pharmacies and health stores provide consumers with access to specialized digestive health and immune-support products, including postbiotic formulations in capsules, tablets and powders. Their established retail networks and focus on health-related products make them an important distribution channel for postbiotic supplement manufacturers.
The segment also benefits from the growing preference for purchasing health products through specialized outlets, where consumers can compare formulations, ingredients and product labels. According to the US Census Bureau’s 2024 Annual Integrated Economic Survey, pharmacies and drug stores generated approximately USD 372.26 billion in sales and reported an annual payroll of approximately USD 30.30 billion. These figures demonstrate the scale of the pharmacy retail industry and its importance in distributing health-related products.
In 2025, the channel benefited from increasing consumer interest in convenient shopping and the availability of health-oriented products through mainstream retail stores. Supermarkets and hypermarkets also provide opportunities for manufacturers to expand product awareness through dedicated nutrition sections, product displays and promotional campaigns. According to the USDA Economic Research Service, grocery stores accounted for 56.2% of US food-at-home expenditures in 2025, demonstrating their substantial role in consumer retail purchasing. Although this figure relates to food expenditure rather than postbiotic supplements, it highlights the established reach of grocery retail channels.
Key Market Segments
By Product
- Capsules and Tablets
- Powders
- Liquids
- Other Formats
By Application
- Digestive Health
- Immune Support
- General Wellness and Other Benefits
- Others
By Distribution Channel
- Hypermarkets and Supermarkets
- Pharmacies & Health Stores
- Online Retail Fastest Growing
- Other off-trade channels
Driver Analysis
Repeat Immune-Support Purchasing
Established immune-support products are moving beyond initial trial toward repeat purchasing, giving postbiotic suppliers recurring ingredient demand rather than dependence on one-time product launches. Kirin reported approximately 30% growth in its iMUSE supplement series during 2025, including approximately 10% growth in its core immune-care supplement; its November 2026 update reported approximately 20% growth in the iMUSE immune supplement series for January–September 2026, with its 30-day multivitamin combination increasing approximately 30% and a 60-day pack launched on 13 October 2026. These are company-reported finished-product results, not global ingredient-market growth rates, and the combination-product contribution is allocated separately below.
Clinical research helps support preparation-specific positioning, but must not be overstated: a November 2025 company presentation described a four-week placebo-controlled study involving 101 Vietnamese medical students, reporting fewer fever- and fatigue-related days; the announcement is not evidence that every postbiotic prevents infection or that all populations achieve the same outcomes.
In an illustrative cohort of 100,000 retained customers, increasing annual consumption from four to six 30-day packs creates six million additional daily servings. At an assumed USD 0.025 of attributable postbiotic ingredient per serving, incremental supplier revenue is USD 150,000, before allowing for displacement of other in-scope products. The +1.2 pp contribution assumes 30% revenue exposure grows 4.0 percentage points faster through genuine purchasing-frequency gains and retained customers, excluding pack-size changes without additional consumption and new geographic placements assigned elsewhere.
Drivers Impact Analysis
| Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Repeat immune-support purchasing | +1.2 pp | Japan; selected Asian supplement markets | Short term (≤ 2 years) |
| Nonviable formulation stability | +1.0 pp | US, Japan, China, Southeast Asia | Short term (≤ 2 years) |
| Multi-benefit supplement integration | +0.9 pp | Japan, Taiwan, China | Short term (≤ 2 years) |
| Established distribution partnerships | +0.8 pp | Europe, Americas, Taiwan, China | Short term (≤ 2 years) |
| Metabolic-health product differentiation | +0.6 pp | US; locally eligible export markets | Medium term (2–4 years) |
Restraint Analysis
Preparation-Specific Evidence Gaps
Evidence supporting a live strain, another inactivation method or a different formulation cannot automatically substantiate the proposed postbiotic, limiting the number of commercially credible ingredients and applications available to supplement customers. ISAPP explicitly states that inactivating a probiotic is insufficient: the resulting preparation must demonstrate a health benefit, and changing the inactivation process can change functionality. Its November 2025 explanation reinforces that clinical evidence must remain relevant to the preparation being marketed, rather than transferred solely because the strain name is unchanged.
The restraint arises when a customer declines an otherwise manufacturable ingredient or application because the relevant benefit has not been demonstrated; routine analytical work and ongoing clinical execution are separate challenges. In an illustrative proposed study enrolling 180 participants, 15% attrition leaves approximately 153 completers. At USD 3,000 per enrolled participant plus USD 160,000 of fixed analytical, statistical and administrative expenditure, the budget is USD 700,000; neither the sample size nor the cost is a universal requirement.
A customer projecting five million annual servings at USD 0.025 of ingredient realization generates only USD 125,000 of annual supplier revenue, making a dedicated study difficult to fund without multiple customers or additional evidence uses. The −0.6 pp deduction assumes 20% revenue exposure grows 3.0 percentage points more slowly through preparation- or population-specific non-awards. Untested preparations are not counted as existing market sales; the deduction concerns foregone incremental commercialization assumed in the driver-inclusive forecast.
Restraint Impact Analysis
| Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Preparation-specific evidence gaps | −0.6 pp | US, Japan, EU, UK | Medium term (2–4 years) |
| Use-specific market-access gaps | −0.4 pp | US | Medium term (2–4 years) |
| Claim-dependent launch rejection | −0.4 pp | US | Medium term (2–4 years) |
| Premium-price purchase rejection | −0.3 pp | US, Japan, UK | Short term (≤ 2 years) |
| Uneconomic shelf-space allocation | −0.3 pp | US, Japan, selected EU markets | Short term (≤ 2 years) |
Opportunity Analysis
Older-Adult Mobility Programs
Community healthy-ageing services and senior-living operators could become additional purchasers of preparation-specific postbiotic supplements through structured mobility programs, extending the customer base beyond standalone immune or digestive products. A January 2025 randomized trial recruited 119 adults aged 65–85 and compared placebo, live PS23 and heat-treated PS23 over 12 weeks; the heat-treated preparation supplied 20 billion cells daily.
Among 100 completers, both active preparations improved selected lower-limb strength and endurance measures, but neither significantly improved muscle mass or upper-limb strength across groups; the detailed report also found no significant between-group difference in the 10-m walking test. These limitations prevent interpreting the study as proof of sarcopenia treatment or universal mobility improvement.
The opportunity is a newly contracted, monitored supplement program using the relevant preparation—not population ageing itself or transferring results from a live strain. In an illustrative network of 200 centers enrolling 100 suitable participants each, one 84-day course creates 1.68 million daily servings. At an assumed USD 0.04 ingredient realization per serving, annual supplier revenue is USD 67,200; if 30% replaces existing postbiotic purchases, net category expansion falls to USD 47,040.
Modest ingredient revenue means the supplier may need several networks to support dedicated evidence and account-management expenditure. The +0.35 pp coefficient assumes 7% revenue exposure grows 5.0 percentage points faster through incremental older-adult contracts, with adherence tracking and appropriately selected functional outcomes, excluding clinical-service revenue and existing consumer sales.
Opportunity Impact Analysis
| Opportunity | (~) % Potential CAGR Upside | Geographic Relevance | Execution Window |
|---|---|---|---|
| Older-adult mobility programs | +0.35 pp | Taiwan; US, Japan subject to eligibility | Medium term (2–4 years) |
| Sports-performance channel contracts | +0.30 pp | Taiwan, US, Japan | Medium term (2–4 years) |
| Dental-channel supplement programs | +0.30 pp | Taiwan; US subject to eligibility | Medium term (2–4 years) |
| Retailer-exclusive evidence platforms | +0.25 pp | US, Japan, Taiwan | Medium term (2–4 years) |
| Validated sleep-support applications | +0.20 pp | Taiwan; selected export markets | Long term (≥ 4 years) |
Challenges Analysis
Fermentation Batch Consistency
Postbiotic production still depends on reproducible microbial cultivation before inactivation, so eliminating the need to preserve live organisms in the finished product does not eliminate upstream biological variability. A June 2025 analytical perspective emphasizes standardized production, defined composition and batch-conformity measurements, while a July 2026 reporting review identifies manufacturing process as an additional source of postbiotic variability beyond strain specificity. Neither publication establishes a universal commercial yield or contamination rate.
In an illustrative 10,000-L fermentation batch, a pre-inactivation concentration of 100 billion cells/mL produces approximately one quadrillion cells before processing. If the next batch reaches 85 billion cells/mL, available cell-equivalent output falls 15% before recovery; compensating through blending or concentration requires additional material or processing time. At an assumed ten billion cell equivalents per daily serving and 80% recovery, theoretical output falls from 80 million to 68 million servings.
These figures describe manufacturing quantity—not biological potency or proof of efficacy. If the lower-yield event affects two of 40 annual batches, the corresponding annualized quantity shortfall is 0.75% before catch-up production, rather than a 15% annual loss. Producers need qualified cell banks, controlled media specifications, monitored fermentation endpoints and preparation-relevant compositional fingerprints. The −0.30 pp contribution assumes 15% revenue exposure grows 2.0 percentage points more slowly through residual batch variability, investigation and unrecovered output, excluding downstream inactivation losses and customer rejection caused by inadequate clinical evidence.
Challenges Impact Analysis
| Challenge | (~) % CAGR Friction Drag | Geographic Relevance | Mitigation Horizon |
|---|---|---|---|
| Fermentation batch consistency | −0.30 pp | Japan, Taiwan, China, US | Medium term (2–4 years) |
| Inactivation process reproducibility | −0.30 pp | Japan, Taiwan, China, Europe | Long term (≥ 4 years) |
| Dose enumeration and release | −0.25 pp | China, Japan, US, EU | Medium term (2–4 years) |
| Formulation and storage stability | −0.20 pp | US, Japan, China, Southeast Asia | Medium term (2–4 years) |
| Multi-site process transfer | −0.15 pp | Japan–Europe, Taiwan–US supply chains | Medium term (2–4 years) |
Geopolitical Impact Analysis
Geopolitical Impact of Ongoing Wars on the Global Iron and Steel Making Market
The ongoing Russia-Ukraine war and escalating conflict in the Middle East are creating significant challenges for the global Iron and Steel Making Market in 2026. These conflicts are affecting energy supplies, raw material availability, transportation networks and international steel trade. Disruptions around the Black Sea and Strait of Hormuz are increasing shipping risks, freight expenses and delivery delays for iron ore, metallurgical coal and finished steel.
According to the OECD Steel Outlook 2026, energy accounts for approximately 20% to 40% of total steel production costs, making the industry highly exposed to geopolitical energy disruptions. The OECD also projects global steel excess capacity to reach 745 million tonnes by 2028, increasing competitive pressure on producers.
The Russia-Ukraine conflict continues to affect European steel supply chains through damaged infrastructure, restricted trade routes and production interruptions. Meanwhile, Middle East instability is increasing energy and freight uncertainty for international steel producers. These conditions are encouraging manufacturers to diversify suppliers, strengthen domestic raw material sourcing and invest in energy-efficient production.
Regional Insights
North America – Dominating Region with Strong Industrial Production
In 2025, North America dominated the Iron and Steel Making Market, accounting for 36.34% share, valued at USD 1.9 billion. The region’s leading position is supported by its established steel manufacturing base, infrastructure investment, automotive production and demand from construction and industrial sectors. The United States remains a major contributor through its integrated steel plants and electric arc furnace facilities.
According to the US Geological Survey (USGS), the United States produced approximately 82 million metric tons of raw steel in 2025, with an estimated sales value of USD 149 billion. The country also had around 105 million metric tons of annual raw steel production capacity. Electric arc furnace production involved 47 companies operating 102 minimills, highlighting the importance of modern steelmaking facilities. Construction accounted for 31% of domestic steel mill shipments, followed by steel service centers and distributors at 26% and automotive at 15%.
Asia-Pacific represents an important growth region for the Iron and Steel Making Market, supported by large-scale manufacturing, infrastructure development and industrial investment. China, Japan and South Korea remain major steel-producing countries, with strong demand from construction, automotive, machinery and engineering industries. According to the World Steel Association, China produced 960.8 million metric tons of crude steel in 2025, while Japan and South Korea produced 80.7 million metric tons and 62.2 million metric tons, respectively. Vietnam also recorded production growth of 12.2% in 2025, reaching 24.7 million metric tons.
Key Regions and Countries Insights
- North America
- US
- Canada
- Europe
- Germany
- France
- The UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- South Korea
- India
- Australia
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- South Africa
- Rest of MEA
Key Players Analysis
DSM-Firmenich AG maintains a strong position in nutrition, health and bioscience through its research capabilities and global ingredient portfolio. In 2025, the company reported total group sales of EUR 12.521 billion, including EUR 9.034 billion from continuing operations. Its adjusted EBITDA from continuing operations reached EUR 1.772 billion. The company operated across nearly 60 countries, employed 28,550 people and maintained 234 sites globally. Its activities are focused on nutritional ingredients, health solutions and scientific innovation.
Cargill, Incorporated is a global agricultural and food ingredient company with operations across multiple industrial sectors. In fiscal year 2025, the company generated annual revenue of USD 154 billion and employed more than 155,000 people worldwide. Its operations covered 70 countries and served 125 markets. Cargill focuses on agricultural supply chains, food ingredients, animal nutrition and bio-based industrial solutions. Its extensive sourcing, processing and distribution network supports its position in global commodity and ingredient markets.
Archer-Daniels-Midland Company (ADM) operates in agricultural processing, human nutrition, animal nutrition and industrial biosolutions. In 2025, the company reported total revenue of USD 80.269 billion, compared with USD 85.530 billion in 2024. Its nutrition segment generated USD 7.512 billion in revenue, reflecting its focus on nutritional ingredients and health-related products. ADM also processed 36.324 million metric tons of oilseeds and 18.525 million metric tons of corn during 2025, supporting its large-scale processing operations.
Top Key Players Outlook
- DSM-Firmenich AG
- Cargill, Incorporated
- Archer-Daniels-Midland Company (ADM)
- Kerry Group plc
- Sabinsa Corporation
- Kirin Holdings Company, Limited
- SCD Probiotics
- Biofarma Group
- Probi AB
- Culturelle (i-Health, Inc.)
- VSL Pharmaceuticals
- Other Key Players
Recent Developments
- In February 9, 2026, DSM-Firmenich AG it agreed to sell its Animal Nutrition & Health business to CVC Capital Partners for an enterprise value of approximately EUR 2.2 billion, while retaining a 20% stake.
- In March 2026, Archer-Daniels-Midland Company (ADM) also launched Akralos Holding Company LLC, a joint venture with Alltech, combining feed manufacturing operations across the United States and Canada. On investment and expansion, ADM reported approximately USD 1.248 billion in capital expenditure during 2025 and projected USD 1.3 billion to USD 1.5 billion for 2026.
Report Scope
| Report Features | Description |
|---|---|
| Market Value (2025) | USD 5.5 Bn |
| Forecast Revenue (2035) | USD 16.5 Bn |
| CAGR (2026-2035) | 11.7% |
| Base Year for Estimation | 2025 |
| Historic Period | 2020-2024 |
| Forecast Period | 2026-2035 |
| Report Coverage | Revenue Forecast, Market Dynamics, Competitive Landscape, Recent Developments |
| Segments Covered | By Product (Capsules and Tablets, Powders, Liquids, Other Formats), By Application (Digestive Health, Immune Support, General Wellness and Other Benefits, Others), By Distribution Channel (Hypermarkets and Supermarkets, Pharmacies & Health Stores, Online Retail, Other off-trade channels) |
| Regional Analysis | North America – US, Canada; Europe – Germany, France, The UK, Spain, Italy, Rest of Europe; Asia Pacific – China, Japan, South Korea, India, Australia, Singapore, Rest of APAC; Latin America – Brazil, Mexico, Rest of Latin America; Middle East & Africa – GCC, South Africa, Rest of MEA |
| Competitive Landscape | DSM-Firmenich AG, Cargill, Incorporated, Archer-Daniels-Midland Company (ADM), Kerry Group plc, Sabinsa Corporation, Kirin Holdings Company, Limited, SCD Probiotics, Biofarma Group, Probi AB, Culturelle (i-Health, Inc.), VSL Pharmaceuticals, Other Key Players |
| Customization Scope | Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. |
| Purchase Options | We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF) |


